2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. Dihydroorotate Dehydrogenase
  5. Dihydroorotate Dehydrogenase Inhibitor

Dihydroorotate Dehydrogenase Inhibitor

Dihydroorotate Dehydrogenase Inhibitors (80):

Cat. No. Product Name Effect Purity
  • HY-135676
    DHODH-IN-12
    		Inhibitor
    DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07.
  • HY-142843
    RORγt/DHODH-IN-1
    		Inhibitor
    RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC50s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity.
  • HY-135678
    DHODH-IN-14
    		Inhibitor
    DHODH-IN-14 (Compound 7l) is a hydroxyfurazan analog of A771726. DHODH-IN-14 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.49 μM for rat liver DHODH. DHODH-IN-14 can be used for rheumatoid arthritis.
  • HY-142847
    RORγt/DHODH-IN-3
    		Inhibitor
    RORγt/DHODH-IN-3 (compound (S)-14d) is a dual RORγt/DHODH inhibitor, with IC50s of 0.098 μM and 0.432 μM, respectively. RORγt/DHODH-IN-3 exhibits remarkable in vivo anti-inflammatory activity.
  • HY-151560
    hDHODH-IN-11
    		Inhibitor
    hDHODH-IN-11 is a potent human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC50 value of 7.2 nM. hDHODH-IN-11 has low cytotoxicity. hDHODH-IN-11 can be used in research of acute myeloid leukemia (AML).
  • HY-116713
    PfDHODH-IN-3
    		Inhibitor
    PfDHODH-IN-3 (compound 2) is an orally active PfDHODH inhibitor with strong antimalarial activity (IC50=47 nM). PfDHODH-IN-3 can inhibit the growth of Plasmodium in animals.
  • HY-159119
    hDHODH-IN-15
    		Inhibitor
    hDHODH-IN-15 (Compound H19) is an inhibitor for human dihydroguanylate dehydrogenase (hDHODH) with an IC50 of 0.21 µM. hDHODH-IN-15 exhibits cytotoxicity in cancer cells NCI-H226, HCT-116, and MDA-MB-231, with IC50 of 0.95-2.81 µM. hDHODH-IN-15 induces ferroptosis in HCT-116, and exhibits antitumor efficacy.
  • HY-135654
    hDHODH-IN-2
    		Inhibitor
    hDHODH-IN-2 is an analogue of the active metabolite of Leflunomide. hDHODH-IN-2 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor. hDHODH-IN-1 has anti-inflammatory activity.
  • HY-151381
    hDHODH-IN-10
    		Inhibitor
    hDHODH-IN-10 is a selective, potent and orally active hDHODH inhibitor, with an IC50 value of 10.9 nM. hDHODH-IN-10 forms hydrogen bonds with key residues Arg136 and Gln47. hDHODH-IN-10 inhibits the proliferation of cancer cells. hDHODH-IN-10 can be used in the research of cancers, such as AML, colorectal cancer.
  • HY-142834
    RORγt/DHODH-IN-2
    		Inhibitor
    RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research.
  • HY-139889
    DHODH-IN-18
    		Inhibitor
    DHODH-IN-18 is a human DHODH inhibitor (IC50 = 0.2 nM).
  • HY-135677
    DHODH-IN-13
    		Inhibitor
    DHODH-IN-13 (Compound 7a) is a hydroxyfurazan analog of A771726. DHODH-IN-13 is a dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 4.3 μM for rat liver DHODH. DHODH-IN-13 can be used for rheumatoid arthritis.
  • HY-149642
    hDHODH-IN-13
    		Inhibitor 99.97%
    hDHODH-IN-13 (compound w2) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 value of 173.4 nM. hDHODH-IN-13 can be used in the research of IBD.
  • HY-157153
    hDHODH-IN-14
    		Inhibitor
    hDHODH-IN-14 (compound 14) is a human dihydroorotate dehydrogenase (hDHODH) inhibitor with an IC50 of 0.469 μM.
  • HY-135562
    Ascofuranone
    		Inhibitor
    Ascofuranone, a prenylphenol antibiotic, is a potent and selective trypanosome alternative oxidase (TAO) inhibitor. Ascofuranone has inhibitory activity against human dihydroorotate dehydrogenase (DHODH). Ascofuranone has diverse physiological activities, including antibiotic, hypolipidemic, anti-inflammatory, and anti-cancer.
  • HY-149030
    DHODH-IN-21
    		Inhibitor
    DHODH-IN-21 (compound 19) is an orally active selective dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 value of 1.1 nM. DHODH-IN-21 has anticancer activity and can be used in studies of acute myeloid leukaemia (AML).
  • HY-158334
    NDs-IN-1
    		Inhibitor
    (Neurodegenerative diseases) NDs-IN-1 (Compound 3g) inhibits the activities of key enzymes such as hBACE-1, hAChE and hMAO-B. NDs-IN-1 is a novel non-covalent multi-target inhibitor. NDs-IN-1 is mainly used in the study of neurodegenerative diseases.
  • HY-144169
    DHODH-IN-19
    		Inhibitor
    DHODH-IN-19 is a potent inhibitor of DHODH. DHODH is present in the inner membrane of human mitochondria and is an iron-containing flavin-dependent enzyme. DHODH-IN-19 inhibits tumor growth. DHODH-IN-19 has the potential for the research of cancer and inflammation disease (extracted from patent WO2021238881A1, compound 1).
  • HY-149877
    hDHODH-IN-12
    		Inhibitor
    hDHODH-IN-12 is a potent DHODH inhibitor with an IC50 value of 0.421 μM. DHODH is the rate-limiting enzyme in the de novo synthesis of pyrimidine which is essential in DNA/RNA Synthesis. hDHODH-IN-12 is present in the inner membrane of human mitochondria.hDHODH-IN-12 can be used for the research of lung cancer.
  • HY-135667
    hDHODH-IN-7
    		Inhibitor
    DHODH-IN-9 (Compound 10k) is an azine-bearing analogue and is a human dihydroorotate dehydrogenase inhibitor. DHODH-IN-9 has antiviral effect with a pMIC50 of 7.4.